Compare · ABSI vs DNA
ABSI vs DNA
Side-by-side comparison of Absci Corporation (ABSI) and Ginkgo Bioworks Holdings Inc. (DNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ABSI focuses on Biotechnology: Commercial Physical & Biological Resarch, while DNA focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- ABSI is the larger of the two at $1.46B, about 2.3x DNA ($623.0M).
- ABSI has been more active in the news (10 items in the past 4 weeks vs 8 for DNA).
- ABSI has more recent analyst coverage (22 ratings vs 18 for DNA).
- Company
- Absci Corporation
- Ginkgo Bioworks Holdings Inc.
- Price
- -
- -
- Market cap
- $1.46B
- $623.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- 2021
- News (4w)
- 10
- 8
- Recent ratings
- 22
- 18
Absci Corporation
Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings, Inc. develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is based in Boston, Massachusetts.
Latest ABSI
- Amendment: SEC Form SCHEDULE 13G/A filed by Absci Corporation
- SEC Form S-3ASR filed by Absci Corporation
- SEC Form 10-Q filed by Absci Corporation
- Absci Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Absci Reports Business Updates and Third Quarter 2026 Financial and Operating Results
- Absci Appoints Gerry Muhle as Chief Commercial Officer to Build Category-Defining Brands for ABS-201 and Its Broader Pipeline
- Chief Executive Officer Mcclain Sean covered exercise/tax liability with 79,860 shares, decreasing direct ownership by 0.93% to 8,552,402 units (SEC Form 4) to satisfy withholding obligation
- Jefferies initiated coverage on Absci Corporation with a new price target
- Absci to Participate in Upcoming Investor Conferences
- AI Can Design Antibodies Faster Than Anyone Can Check Them for Immune Risk. That Gap Is Starting to Close.
Latest DNA
- SEC Form 10-Q filed by Ginkgo Bioworks Holdings Inc.
- Ginkgo Bioworks Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo
- SEC Form 8-K filed by Ginkgo Bioworks Holdings Inc.
- Officer Coen Steven P. sold $7,770 worth of shares (766 units at $10.14) (SEC Form 4)
- Officer Shetty Reshma P. sold $417,608 worth of shares (41,172 units at $10.14) (SEC Form 4)
- Large owner Canton Barry sold $417,608 worth of shares (41,172 units at $10.14) (SEC Form 4)
- Officer Kelly Jason R sold $463,353 worth of shares (45,682 units at $10.14) (SEC Form 4)
- Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science Program
- Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-Loop